<DOC>
	<DOC>NCT02671071</DOC>
	<brief_summary>The primary objective of this study is to describe the socio-demographic, clinical pathological, quality of life and treatment characteristics of patients diagnosed with CC in Brazil.</brief_summary>
	<brief_title>Prospective Evaluation of Patients With Uterine Cervical Cancer in Brazilian Health Institutions - The EVITA I Study</brief_title>
	<detailed_description>The primary objective of this study is to describe the socio-demographic, clinical pathological, quality of life and treatment characteristics of patients diagnosed with cervix cancer (CC) in Brazil. Other specific objectives are: - To describe socio-demographic characteristics: age at diagnosis, education, family income, race, occupation, personal health habits - e.g.oral contraceptive use ever/never and duration; smoking never/ever/current/duration , ever drinking), sexual history, insurance coverage (private, public), institution (private, public, philanthropic), obstetric history, comorbidities, performance status, human papillomavirus vaccination or not - To describe the screening for CC: access, type, frequency and results. - To describe clinical pathological characteristics of CC: histology (adeno x squamous x adenosquamous x neuroendocrine x other) , International Federation of Gynecology and Obstetrics (FIGO) stage, pathological stage, exams for staging, date of diagnosis, site of metastasis. - To describe treatment characteristics of CC: date of surgery, type of surgery; date and duration of radiotherapy, type of radiotherapy; date, type and lines of systemic therapy (chemotherapy, monoclonal antibodies), - To describe treatment safety (grade 3-4 AEs, death due to treatment toxicity, discontinuation due to AE). In addition adverse events of special interest will be described (details on Safety section). - To describe the outcomes: follow-up exams and date of visits, persistent disease, recurrence, progression times in metastatic disease, complications (e.g. hydronephrosis/nephrostomy/ GI perforations and both GI &amp; genitourinary fistulae.), death due CC and death from any cause.</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>Histologic confirmed invasive cervical cancer Diagnosis of FIGO stages Stage 1B to 2A high risk 2B4B or recurrent disease Patients â‰¥18 years old 1. Noninvasive uterine carcinoma; 2. Pregnancy; 3. synchronous tumor or second primary tumor in the past 5 years (except thyreoid ancer or nonmelanoma skin cancer).</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cervix Cancer</keyword>
</DOC>